Kantor, Olga
Wakeman, Melia
Weiss, Anna
Wong, Stephanie
Laws, Alison
Grossmith, Samantha
Mittendorf, Elizabeth A.
King, Tari A.
Funding for this research was provided by:
Rob and Karen Hale Distinguished Chair in Surgical Oncology
Pamela and Nick Gelsomini Breast Surgical Oncology Fellowship Fund
Article History
Received: 21 May 2020
Accepted: 14 August 2020
First Online: 31 August 2020
Disclosures
: Elizabeth A. Mittendorf reports the following personal financial interests: research support for laboratory from GlaxoSmithKline; honoraria from Physician Education Resource; compensated service on Scientific Advisory Boards for Astra-Zeneca, Exact Sciences (formerly Genomic Health), Merck, Peregrine Pharmaceuticals, Roche/Genentech, Sellas Lifesciences, TapImmune Inc; and uncompensated service on steering committees for BMS, Lilly, Roche/Genentech. She also reports the following institutional financial interests: MD Anderson: clinical trial funding from AstraZeneca, EMD Serono, Galena Biopharma, Roche/Genentech; DFCI: clinical trial funding from Roche/Genentech (via an SU2C Grant); and the following non-financial interests and non-remunerated activities: Board of Directors: American Society of Clinical Oncology, Scientific Advisor: Susan G. Komen for the Cure Foundation. Tari A. King reports speaker’s fees and advisory board participation for Exact Sciences (formally Genomic Health).